0 avis
Genomic landscape of hyperleukocytic acute myeloid leukemia
Archive ouverte
Edité par CCSD ; Nature Publishing Group -
This work has been grant-funded by the CHU de Toulouse (local grant 2018), the Toulouse Cancer Santé Foundation (Toulouse Cancer Health Foundation), the FONROGA Foundation, and the Ligue Contre le Cancer (Anti-Cancer League) Foundation (AO 2018). International audience. Approximately 20% of patients with acute myeloid leukemia (AML) present at diagnosis with hyperleukocytosis, which is commonly defined as a white blood cell count > 50 ×109 /L or >100 ×109 /L. Hyperleukocytic AML is an oncological emergency because the risk of early death is significant due to leukemic organinfiltration, leukostasis syndrome, disseminated intravascular coagulopathy and tumour lysis syndrome. Early management of these symptoms as well as rapid leukoreduction are critical in the therapeutic management.In the era of next-generation sequencing (NGS), considerable progress has been made in understanding the genetic diversity of AML. However, owing to the small proportion of hyperleukocytic patients generally included in clinical trials, the genomic landscape of hyperleukocytic AML and the prognostic impact of genetic lesions in this specific clinical context have not been described in detail except in a recent study from Taiwan which reported the frequency of mutations in a panel of 20 yeloidgenes.
Consulter en ligne
Suggestions
Du même auteur
